Overview
Lobbying Costs
150,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
1.5 Fte (4)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Otsuka Novel Products GmbH (ONPG)
EU Transparency Register
260256215861-19 First registered on 02 Feb 2015
Goals / Remit
Otsuka Novel Products GmbH (ONPG), based in Munich, Germany, was founded by the global Otsuka-group in 2010. The main focus of the company is the therapeutic area of tuberculosis.
Main EU files targeted
- Commission's Communication on a One-Health Action Plan to support Member States in the fight against Antimicrobial Resistance (AMR)
- Agenda 2030 for Sustainable Development
- Roadmap to implement the tuberculosis action plan for the WHO European Region 2016–2020Address
Head Office
Erika-Mann-Str. 21
München 80636
GERMANY -
People
Total lobbyists declared
4
Employment time Lobbyists 50% 2 25% 2 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
https://www.eu-pearl.eu/
https://www.amrindustryalliance.org/Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
150,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
It is Otsuka Novel Products GmbH goal to increase awareness of Global tuberculosis pandemic, to improve access to diagnostic und medicines, rapid and equitable access to pharmaceuticals worldwide. Therefore, Otsuka is working with industry partners, governments, NGOs, health agencies in tuberculosis high burden countries.
1. Otsuka is member of EU Patient-Centric Clinical Trial Platforms EU PEARL - https://www.eu-pearl.eu/
This project is funded by the Innovative Medicines Initiative (IMI), a large, far-reaching public-private partnership integrated by the European Union and the pharmaceutical industry to support research and innovation in life-science.
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a tested and trusted framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial.
2. Otsuka is member of the Antimicrobial Resistance initiative (AMR) - https://www.amrindustryalliance.org/
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces. Antimicrobial resistance poses a formidable threat to the attainment of the Sustainable Development Goals (SDGs). The United Nations called in 2016 for concerted action from governments and various sectors to address the implications of antimicrobial resistance in a comprehensive manner, and implement strategies at national level.
The AMR Industry Alliance is the life-sciences industry response to the call for action.Other activities
Otsuka is member of the Innovative Medicines Initiative (IMI).
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 04 Feb 2015 Location Brussels,Belgium Subject EU health policy DG Günther Oettinger Attending - Günther Oettinger (Commissioner)
- Meetings